Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned a consensus rating of “Hold” from the thirty ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, twelve have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $489.29.

Several research analysts have recently commented on REGN shares. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Piper Jaffray Companies lifted their price target on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a report on Tuesday, June 20th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $484.00 price target (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Leerink Swann reaffirmed an “outperform” rating and issued a $493.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, June 13th. Finally, Citigroup Inc. reaffirmed a “buy” rating and issued a $575.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, September 7th.

In related news, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Insiders sold a total of 89,468 shares of company stock worth $42,312,448 over the last quarter. Insiders own 10.80% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. BlackRock Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 3,331.5% in the 1st quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after purchasing an additional 5,967,733 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Regeneron Pharmaceuticals by 15,495.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after purchasing an additional 1,552,948 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Regeneron Pharmaceuticals by 74.1% in the 2nd quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after purchasing an additional 550,247 shares in the last quarter. Janus Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 58.5% in the 1st quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after purchasing an additional 486,119 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after purchasing an additional 416,192 shares in the last quarter. Institutional investors and hedge funds own 67.41% of the company’s stock.

Shares of Regeneron Pharmaceuticals (REGN) traded down 1.77% during midday trading on Wednesday, hitting $452.97. 1,197,831 shares of the stock were exchanged. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55. The firm has a 50-day moving average price of $460.12 and a 200-day moving average price of $454.49. The company has a market cap of $48.03 billion, a PE ratio of 45.44 and a beta of 1.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the business posted $2.82 EPS. The company’s quarterly revenue was up 21.2% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals will post $14.92 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/regeneron-pharmaceuticals-inc-regn-given-consensus-rating-of-hold-by-analysts.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.